23948sdkhjf
Logga in eller skapa för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.

Meda gets access to Asia

The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.
Meda has acquired







Onsolis is a potential



Meda already holds



BDSI and Meda have



world-wide rights to the drug Onsolis from Meda’s collaboration partner Biodelivery Sciences International, BDSI. The product, which is currently in registration phase, has been documented for treatment of breakthrough cancer pain in opioid tolerant patients. treatment for breakthrough pain, which means episodes of severe pain, in opioid tolerant patients with cancer. Onsolis consists of a small, dissolvable, polymer film, formulated with the opioid narcotic fentanyl for application to the inner lining of the cheek. exclusive rights to Onsolis in the US, EU, Canada and Mexico from previous agreements with BDSI. The new agreement grants Meda the rights outside these countries and access to interesting markets such as Russia, Japan, South East Asia and Australia. A one time cash payment of USD 3 million has been made to BDSI for these rights and no further milestone payments are due. also reached agreement of a USD 3 million advance payment on the FDA approval milestone which is anticipated during the second quarter of 2009. Consequently, that milestone has been reduced from USD 30 million to about USD 27 million.

BREAKING
{{ article.headline }}
0.08